Evidence-based use of adjunctive therapies to ventilation.
Respiratory distress is the most common reason for admission to newborn intensive care units. Over the past two decades, we have witnessed a revolution in the therapies that are used to manage neonates who have pulmonary disorders. Multiple adjunctive agents have also been used in an attempt to mitigate the course of neonatal lung disease. The disorders we discuss include respiratory distress syndrome, chronic lung disease/bronchopulmonary dysplasia, persistent pulmonary hypertension of the newborn, meconium aspiration syndrome, and transient tachypnea of the newborn. We review the evidence that either supports or refutes the use of adjunctive therapies for these disorders.
Wiswell
Thomas E
TE
Center for Neonatal Care, Florida Hospital Orlando, 2718 North Orange Avenue, Suite B, Orlando, FL 32804, USA. thomas_wiswell@yahoo.com
Tin
Win
W
Ohler
Kirsten
K
D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000188:drug therapy / Q000628:therapy*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy; D012138:Respiratory Therapy